You just read:

Merck KGaA, Darmstadt, Germany Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations

News provided by

Merck KGaA

Jun 03, 2019, 10:25 ET